Skip to main content

NCBiotech News

  • The 20th anniversary celebration of Biogen RTP was an opportunity to honor the site’s past, present and pending triumphs.
  • Durham-based Baebies Inc. has completed $13 million in equity financing to commercialize technology that can screen for genetic disorders in newborns from tiny amounts of bodily fluids such as dried blood or saliva.
  • North Carolina’s Raleigh-Durham region, a.k.a. the Research Triangle, has the nation’s second leading life science base among major metro areas, up from No. 4 since last year, according to a new JLL report.
  • Bioscience briefs with names making news
  • The North Carolina Biotechnology Center awarded 27 loans and grants totaling about $1.8 million to companies and universities across the state during the final quarter of its 2014-2015 fiscal year ending June 30. Altogether, the Center made 82 loans and grants totaling $6,786,852 during the year just ended.
  • If anybody questions the importance of North Carolina’s foothold on agricultural biotechnology, have them talk to a local resident who knows firsthand: Mary-Dell Chilton, Ph.D. She is, after all, the mother of plant genetic modification.
  • After two decades as Research Triangle Park neighbors, including recent years as manufacturing partners, the Biogen and Eisai biopharmaceutical factories are about to consolidate under the Biogen banner.
  • Scioderm, a Durham-based biopharmaceutical company, has agreed with the U.S. Food and Drug Administration to submit a rolling New Drug Application (NDA) for Zorblisa, its topical therapy for the treatment of blisters and lesions in patients with epidermolysis bullosa, a rare genetic disease.
  • NCBiotech grant support helps Piedmont Triad nanoscientists pursue commercialization of potentially useful applications in reproducing the intricate ways insects' exteriors are constructed.
  • High Point clinical-stage pharmaceutical company vTv Therapeutics has filed a registration statement with the U.S. Securities and Exchange Commission to raise up to $173 million in an initial public offering of shares of its Class A common stock.
  • AgBiome of Research Triangle Park has formed a strategic partnership with Genective, a French company that develops biotech corn seed, to discover new ways to control insects in crops.
  • Bioscience briefs with names making news
  • A high-profile collaboration announced today by Durham biopharmaceutical company Spyryx Biosciences is the latest in a string of breathtaking announcements by three young Durham companies with promising treatments for deadly lung diseases.
  • T3D Therapeutics, a young Research Triangle Park company started with loan help from the North Carolina Biotechnology Center, has received approval from the Food and Drug Administration to test its lead drug candidate in patients with Alzheimer’s disease.
  • Bayer CropScience continued to dazzle observers at its North American and global Seeds headquarters today with a grand opening of a $33 million office renovation project while also breaking adjacent ground for a $34 million research greenhouse.
  • Timothy “Timm” Crowder, Ph.D., an entrepreneurial expert in design and development of inhaler technologies for lung therapies, has joined pharmaceutical startup Spyryx Biosciences as vice president of technical operations.
  • The president of Chapel Hill pharmaceutical start-up Eppin Pharmasays a $75,000 loan late last year from the North Carolina Biotechnology Center was an “absolutely critical” lead-in to a $225,000 NIH grant announced today.
  • When it comes to the $24 billion outsourced drug development industry, North Carolina is the undisputed – and still undefeated – heavyweight champion of the world. It's home to 128 contract research organizations employing over 21,000 people within the state and tens of thousands of others around the world.
  • North Carolina has substantial university and company assets devoted to health informatics, a quickly evolving SuperScieNCe field that uses databases, electronic medical records, bioinformatics and other tools to support clinical decisions that improve health care efficiency, delivery and outcomes.
  • Delivering precise treatments customized for each person’s unique genetic makeup is the powerful promise of personalized medicine, and North Carolina is already a leader in this new era of genomics-based health care.

Pages

Subscribe to News & Events